# Short-Term Exposure to a 50 Hz Extremely Low-Frequency Electromagnetic Field (ELF-EMF) Leads to ROS-Mediated DNA Damage in Gynecological and Urological Cancer Cells In Vitro

**Authors:** Gabriela Betlej, Ewelina Bator, Aleksandra Kwiatkowska, Maria Romerowicz-Misielak, Anna Koziorowska, Marek Koziorowski, Iwona Rzeszutek

PMC · DOI: 10.3390/ijms27041630 · International Journal of Molecular Sciences · 2026-02-07

## TL;DR

Short-term exposure to a 50 Hz electromagnetic field increases DNA damage in gynecological and urological cancer cells through ROS production.

## Contribution

This study shows that short-term ELF-EMF exposure induces ROS-mediated DNA damage in specific cancer cell lines.

## Key findings

- Exposure to 50 Hz ELF-EMFs increased ROS levels in HeLa, ES-2, and DU-145 cancer cells.
- ES-2 and DU-145 cells showed significant changes in DNA repair-related gene and protein expression after 30 min of exposure.
- Short-term ELF-EMF exposure may offer a potential treatment strategy for gynecological and urological cancers.

## Abstract

The effect of sinusoidal Extremely Low-Frequency Electromagnetic Fields (ELF-EMFs) on gynecological (HeLa, ES-2) and urological (DU-145) cancer cells was investigated. ELF-EMFs with a frequency of 50 Hz and a magnetic flux density of 1.3 mT were applied for 15 and 30 min. The experiment was conceptualized to investigate the in vitro short-term effects of ELF-EMFs on cell reactive oxygen species (ROS) formation, the levels of genes and proteins involved in DNA damage response, and epigenetic modifications. Here, we found that ELF-EMFs treatment leads to an elevation in the ROS levels that contribute to distinct scenarios in the studied cancer cells. The most prominent changes in the studied factors were found in ES-2 and DU-145 cells exposed to 30 min of ELF-EMFs. ES-2 cells exhibited upregulation of XRCC5 gene expression and elevated levels of several proteins: TNF-α, RAD51, APE1, XRCC1, and NSUN2. Diminished levels of BCL-2, HSP90, RAD51, and TNF-α, as well as overexpression of VIM and METTL3, were observed in DU-145 cells. In summary, we postulate that short-term exposure to 50 Hz ELF-EMFs may be a promising treatment strategy for gynecological and urological cancer cells.

## Linked entities

- **Genes:** XRCC5 (X-ray repair cross complementing 5) [NCBI Gene 7520], BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596], HSP90AA1 (heat shock protein 90 alpha family class A member 1) [NCBI Gene 3320], RAD51 (RAD51 recombinase) [NCBI Gene 5888], TNF (tumor necrosis factor) [NCBI Gene 7124], VIM (vimentin) [NCBI Gene 7431], METTL3 (methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit) [NCBI Gene 56339], APEX1 (apurinic/apyrimidinic endodeoxyribonuclease 1) [NCBI Gene 328], XRCC1 (X-ray repair cross complementing 1) [NCBI Gene 7515], NSUN2 (NOP2/Sun RNA methyltransferase 2) [NCBI Gene 54888]
- **Proteins:** TNF (tumor necrosis factor), RAD51 (RAD51 recombinase), APEX1 (apurinic/apyrimidinic endodeoxyribonuclease 1), XRCC1 (X-ray repair cross complementing 1), NSUN2 (NOP2/Sun RNA methyltransferase 2), BCL2 (BCL2 apoptosis regulator), HSP90AA1 (heat shock protein 90 alpha family class A member 1)

## Full-text entities

- **Genes:** BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, MAP1LC3B (microtubule associated protein 1 light chain 3 beta) [NCBI Gene 81631] {aka ATG8F, LC3B, MAP1A/1BLC3, MAP1LC3B-a}, XRCC1 (X-ray repair cross complementing 1) [NCBI Gene 7515] {aka RCC, SCAR26}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, METTL3 (methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit) [NCBI Gene 56339] {aka IME4, M6A, MT-A70, Spo8, hMETTL3}, H2AX (H2A.X variant histone) [NCBI Gene 3014] {aka H2A.X, H2A/X, H2AFX}, APEX1 (apurinic/apyrimidinic endodeoxyribonuclease 1) [NCBI Gene 328] {aka APE, APE1, APEN, APEX, APX, HAP1}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, XRCC6 (X-ray repair cross complementing 6) [NCBI Gene 2547] {aka CTC75, CTCBF, G22P1, KU70, ML8, TLAA}, POLB (DNA polymerase beta) [NCBI Gene 5423], HSP90AA1 (heat shock protein 90 alpha family class A member 1) [NCBI Gene 3320] {aka EL52, HEL-S-65p, HSP86, HSP89A, HSP90A, HSP90N}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, RBMS3 (RNA binding motif single stranded interacting protein 3) [NCBI Gene 27303], RAD51 (RAD51 recombinase) [NCBI Gene 5888] {aka BRCC5, FANCR, HRAD51, HsRad51, HsT16930, MRMV2}, VIM (vimentin) [NCBI Gene 7431], XRCC5 (X-ray repair cross complementing 5) [NCBI Gene 7520] {aka KARP-1, KARP1, KU80, KUB2, Ku86, NFIV}, NSUN2 (NOP2/Sun RNA methyltransferase 2) [NCBI Gene 54888] {aka MISU, MRT5, SAKI, TRM4}, OGG1 (8-oxoguanine DNA glycosylase) [NCBI Gene 4968] {aka HMMH, HOGG1, MUTM, OGH1}, ELAVL1 (ELAV like RNA binding protein 1) [NCBI Gene 1994] {aka ELAV1, HUR, Hua, MelG}, HMOX2 (heme oxygenase 2) [NCBI Gene 3163] {aka HO-2}
- **Diseases:** leukemia (MESH:D007938), Gynecological and Urological Cancer (MESH:D014571), metastasis (MESH:D009362), osteoporosis (MESH:D010024), infection (MESH:D007239), ovarian cancer (MESH:D010051), breast cancer (MESH:D001943), urological (MESH:D014570), mitochondrial dysfunction (MESH:D028361), pain (MESH:D010146), cervical cancer (MESH:D002583), prostate and cervical cancer (MESH:D011471), injury to (MESH:D014947), inflammation (MESH:D007249), Cancer (MESH:D009369), tumorigenesis (MESH:D063646), cervical (MESH:D002575)
- **Chemicals:** penicillin (MESH:D010406), DOX (MESH:D004317), H2O2 (MESH:D006861), cisplatin (MESH:D002945), DMEM (-), superoxide (MESH:D013481), Hoechst 33342 (MESH:C017807), CO2 (MESH:D002245), L-glutamine (MESH:D005973), m6A (MESH:C005955), ifosfamide (MESH:D007069), ROS (MESH:D017382), docetaxel (MESH:D000077143), Texas Red (MESH:C034657), DHE (MESH:C067883), metal (MESH:D008670), streptomycin (MESH:D013307), FITC (MESH:D016650), methotrexate (MESH:D008727), Hydroxyl (MESH:D017665)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** ES-2 — Homo sapiens (Human), Embryonic stem cell (CVCL_C769), G401 — Homo sapiens (Human), Rhabdoid tumor of the kidney, Cancer cell line (CVCL_0270), ARPE-19 — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0145), RGC-5 — Mus musculus (Mouse), Transformed cell line (CVCL_4059), DU-154 — Homo sapiens (Human), Amelanotic melanoma, Cancer cell line (CVCL_5528), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030), HL-60 — Homo sapiens (Human), Adult acute myeloid leukemia with maturation, Cancer cell line (CVCL_0002), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), 1C — Pan troglodytes (Chimpanzee), Induced pluripotent stem cell (CVCL_1G30), L929 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_AR58), ZR-75-1 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0588), DU-145 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0105), K562 — Homo sapiens (Human), Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_0004), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940628/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940628/full.md

## References

62 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940628/full.md

---
Source: https://tomesphere.com/paper/PMC12940628